Menopausal hormone therapy (MHT), previously known as hormone replacement therapy (HRT), is experiencing a global resurgence, prompting a closer examination of its benefits and risks for women navigating this natural biological transition. While not a disease, menopause can significantly disrupt sleep, work, relationships, and overall quality of life for millions.
Information was available with The Chenab Times that clarifies the current understanding of MHT. This therapy is recognized as the most effective treatment for managing hot flushes and night sweats, symptoms that can severely impact a woman’s well-being. Beyond symptom relief, MHT can also contribute to preventing bone loss and reducing the risk of fractures, common concerns during and after menopause.
Understanding Menopause and Its Impact
Natural menopause is medically defined as 12 consecutive months without menstruation, provided no other underlying cause explains the absence of periods. In India, the average age of menopause typically falls in the late forties, around 47 years, though individual and regional variations are observed. The perimenopausal phase, a transitional period lasting several years, often precedes menopause, characterized by irregular menstrual cycles and fluctuating hormone levels. The decline in ovarian function affects multiple organs; decreasing estrogen levels can disrupt the brain’s temperature regulation, leading to hot flushes and night sweats. Furthermore, vaginal and urinary tissues may thin and lose elasticity, causing dryness, discomfort, and urinary issues. Bone density loss accelerates around menopause, increasing the risk of osteoporosis. Changes in body fat distribution, with a tendency to accumulate around the abdomen, alongside potential alterations in muscle mass, cholesterol levels, insulin sensitivity, and blood pressure, are also common. Not all women experience menopause uniformly; some notice minimal changes, while others endure prolonged struggles. In India, symptoms like fatigue and body aches are often attributed to aging or domestic responsibilities, and vaginal and sexual symptoms frequently go unaddressed due to embarrassment or societal taboos. It is also crucial to recognize that not all complaints are solely hormonal in nature.
The Potential of Menopausal Hormone Therapy
MHT stands out as the most potent intervention for alleviating hot flushes and night sweats, thereby improving sleep, mitigating other menopausal symptoms, and enhancing a woman’s overall quality of life. It also plays a vital role in preventing bone density loss and reducing fracture incidence. For localized genitourinary symptoms such as vaginal dryness and painful intercourse, low-dose vaginal estrogen treatments can be particularly effective. There is an increasing focus on estrogen’s potential to promote healthspan—the period of life lived in good health. However, definitive evidence supporting MHT’s ability to extend longevity remains incomplete. It is not a panacea for anti-aging, nor should it be routinely prescribed for the prevention of heart attacks, dementia, cognitive decline, or for weight loss, as these benefits are currently insufficiently established. The key consideration is the degree to which a woman’s suffering impacts her daily life.
For healthy women experiencing bothersome menopausal symptoms, the benefits of MHT generally outweigh the risks when initiated before the age of 60 or within ten years of menopause. While these are practical clinical guidelines, they are not absolute cut-offs. In the Indian context, some experts suggest that treatment is most appropriate for women below 55 years of age and within five years of menopause. Therapy can also be considered during perimenopause when symptoms are problematic, even before menstruation ceases entirely.
To manage hot flushes and night sweats, estradiol can be administered orally or transdermally via patches or gels. To minimize the risk of blood clots, transdermal estrogen, such as skin patches, is often preferred as it bypasses the liver’s first-pass metabolism of oral estrogen. Women who still have their uterus require a progestogen in conjunction with systemic estrogen to safeguard the uterine lining. Oral micronized progesterone is the favored choice. Sequential therapy, where progestogen is taken for a portion of each month, typically results in a withdrawal bleed. Continuous combined therapy, involving both estrogen and progesterone throughout the cycle, aims to eliminate scheduled bleeding and is generally used later in the menopausal journey. Women who have undergone a hysterectomy can safely use estrogen-only therapy.
Weighing the Advantages and Disadvantages
MHT is not a monolithic treatment; its risk profile varies significantly based on factors such as age, the specific formulation used, the route of administration, duration of treatment, and an individual’s medical history. In suitable candidates, particularly younger women, MHT can offer substantial symptom relief with a clearly favorable benefit-risk ratio, especially when employing transdermal estrogen and micronized progesterone. The risk of breast cancer associated with MHT is also influenced by age, regimen, and duration. Combined estrogen-progestogen therapy may elevate breast cancer risk with prolonged use in older women (typically over 60), whereas estrogen-only therapy generally presents a more favorable risk profile in this regard. Certain hormone-sensitive cancers, including breast, uterine/endometrial, ovarian, and thyroid cancer, along with a history of unexplained vaginal bleeding, previous or active blood clots, stroke, and significant liver disease, may contraindicate systemic MHT or necessitate specialist evaluation. Before prescribing, clinicians must thoroughly review a patient’s symptoms, medical history, breast and gynecological health, cardiovascular and clotting risks, blood pressure, and ensure relevant screenings, including mammography, are up-to-date. Treatment efficacy and safety should be reassessed approximately three months after initiation and periodically thereafter, usually annually once the patient is stable.
Effective menopause care necessitates moving beyond extremes, avoiding both the over-medicalization of every woman as hormone-deficient and the outright denial of treatment due to fear. MHT can be a highly effective option for appropriately selected women, but its benefits and risks are dynamic, changing with age and individual circumstances. The objective is not to universally prescribe hormones or to withhold them from those who could benefit, but rather to empower women to navigate these years with comfort, confidence, and good health.
The Chenab Times News Desk